Correspondence 997 transcripts A and B considerably differ from that of the type I transcripts previously described. 1 In comparison with the type I transcripts previously reported, transcripts A and B lack 124 nucleotides in the 3′ region of E2A exon 13; contain 137-bp or 90-bp, respectively, of intervening sequence of unknown origin; and do not contain nucleotides from intron 13 of E2A and intron 3 of HLF. Since no sequence homologous to either of the two intervening sequences could be found on a search in Genbank, these intervening sequences were newly acquired untemplatedly. Since transcript A cannot generate a full-length, functional protein and since its expression was much lower than the expression of transcripts B and C, this gene product may not play an important role in the process of leukemogenesis in t(17;19) ALL.
Do transcriptionally silent BCR-ABL cells persist in CML patients in molecular remission after stem cell transplantation?
TO THE EDITOR The only current curative treatment for chronic myeloid leukemia (CML) is allogeneic stem cell transplantation (SCT). However, relapses occur in 10-30% of patients transplanted in chronic phase and even more frequently in patients transplanted in later phases of CML. As relapses can appear after long-term molecular remissions detected by nested RT-PCR for BCR-ABL transcript, the question arises of what is the origin of cells whose activation results in a relapse. A rational explanation seems to be the persistence of cells with an unexpressed BCR-ABL gene. The question of existence of such transcriptionally silent BCR-ABL cells was addressed by several authors with contradictory conclusions. Zhang et al, 1 when comparing the results of genomic DNA PCR for BCR-ABL with RT-PCR, found that CML patients in remission after SCT do not generally harbor a substantial pool of transcriptionally silent BCR-ABL cells. On the other hand, Chomel et al negative or only weakly positive (BCR-ABL/ABL close to 0.002%). In two patients with a sex-mismatched donor, the level of cells with the BCR-ABL genomic rearrangement was also confirmed by FISH using X and Y chromosome probes. The detected amount of quiescent cells is surprisingly high, particularly in patients after SCT (3-11%). This finding does not correspond with the results of the above authors 1 and also with our own experience. Our considerations result from the comparison of hematopoietic mixed chimerism analyses based on genomic DNA PCR for a variable number of tandem repeat (VNTR) sequences, and the level of BCR-ABL transcripts in peripheral blood samples from patients with CML after SCT. The chimerism analyses can identify the proportion of recipient and donor blood cells in post-SCT patients but do not distinguish between leukemic and normal recipient cells. However, the number of host cells clearly determines the highest possible number of leukemic cells while, on the other hand, the absence of host cell DNA unambiguously excludes the presence of leukemic cells with BCR-ABL genomic rearrangement of host cell origin at the sensitivity level of the method. The sensitivity of PCR for various VNTR loci, assessed by dilution of recipient cells into donor cells, was found to be 5-0.8% for ApoBII, Col2A1, YNZ22, HVR-Ig and TPO loci (higher sensitivity for short recipient alleles); 0.5% using D1S80 and MCT118 locus; 0.1-0.01% for AMG sex specific locus and 0.1-0.01% in 1st PCR and 0.001-0.0001% in 2nd PCR of two-step nested PCR for the sex-specific locus DYZ1 in female-male donor-recipient pairs. 3 The presence and amount of the BCR-ABL transcripts were detected by qualitative and quantitative competitive two-step RT-PCR with a sensitivity of 0.001-0.0001% (10 ). 4 We examined sequential samples of 25 patients with CML after SCT. The follow-up was carried out for the period of 6 months to 6 years after SCT. All patients tested were informative at least for two VNTR assays with a sensitivity of 5-0.5%, some of them for sex-specific assays with a higher sensitivity. Direct comparison of the two methods could be performed in 181 samples, of which 107 were RT-PCR for BCR-ABL negative. Of these 107 samples with negative RT-PCR, only eight samples (7.5%) exhibited mixed chimerism. The level of the host-derived DNA did not exceed 5% (Table 1) . In all these samples, analyses by conventional cytogenetic methods, if available, were Ph negative. Thus, only in 7.5% of the samples can we assume the presence of cells with unexpressed BCR-ABL gene at the level presented by Chomel et al. 2 However, in some of these samples normal hematopoiesis without BCR-ABL rearrangement might be involved. Sequential analyses also showed that the findings of host genomic DNA were always only transient (in four patients in one sample, in two patients in two consecutive samples). Moreover, in the four patients with the discordant result in a single sample, the analysis was performed in the early stage after SCT (4 weeks), when cells surviving the conditional regimen but unable to express BCR-ABL or T cells without BCR-ABL rearrangement could be present. On the basis of these results we cannot presume that the persistence of a significant number of BCR-ABL transcriptionally silent cells is a general feature in patients in molecular remission after SCT.
Leukemia
Besides the above study, we tested 47 samples from six male patients in remission after sex-mismatched allografts to be able to detect the host genomic DNA by the sex-specific DYZ1 locus with sensitivity comparable to RT-PCR for BCR-ABL (Table 2 ). In all 47 Table 2 Comparison samples, the RT-PCRs for BCR-ABL were negative or only weakly positive; classical cytogenetic analyses, if available, were Ph negative. Seven samples from a patient with a stable BCR-ABL RT-PCR positivity under 0.007% were simultaneously permanently positive in 2nd PCR for DYZ1. Forty samples from the other five patients, which were negative in RT-PCR for BCR-ABL, were negative for DYZ1 or positive only in 2nd PCR. None of the 47 samples were positive either in the 1st PCR for DYZ1 or in VNTR assays other than DYZ1. The weak DYZ1 positivity, found in some peripheral blood samples negative for BCR-ABL transcripts, might point to the existence of transcriptionally silent BCR-ABL cells in the range of 0.0001-0.01%. We cannot of course exclude the possible presence of non-leukemia hematopoiesis of host origin. This could touch on another interesting problem, the specificity of graft-versus-leukemia effect. The presence of non-leukemia hematopoiesis may indicate that anti-leukemic rather than antihost effect is involved in these cases. However, we must keep in mind that this weak positivity may be caused by a minute admixture of male recipient cells of non-blood origin whose elimination is difficult in such chimeras, even if all strict precautions are taken. In conclusion, this study also does not confirm the existence of a significant number of dormant leukemic cells with unexpressed BCR-ABL gene. These results do not exclude the presence of transcriptionally silent cells in an amount lower than the detection limit of our methods. A rare subpopulation of highly quiescent primitive leukemic cells was described in CML patients in chronic phase. 5 These cells may or may not be eradicated by SCT. However, also patients with negative RT-PCR tests may still harbor up to a million transcriptionally active BCR-ABL cells, which can be the cause of the reappearance of the disease. Such cells must be under the control of the immune system, whose failure may result in a relapse.
Molecular monitoring of mixed chimerism is generally used to assess the engraftment of donor cells after SCT and, in some laboratories, to predict post-SCT relapse. Complete donor chimerism, ie the absence of host cell DNA, indicates full donor engraftment and disease remission. Disease recurrence, in the predominant majority of patients, is first signalized by increasing BCR-ABL RT-PCR positivity and then by increasing mixed chimerism caused by the higher sensitivity of RT-PCR assay. 3, 6 Our present results are concordant with these studies.
In conclusion, our results cannot exclude the presence of a minute amount (up to 0.01%) of transcriptionally silent BCR-ABL cells in CML patients in molecular remission after SCT but they did not confirm the general persistence of these cells at such a high rate (3-11%) as found by Chomel et 
